Aiming, We've seen the disastrous consequences of arriving at conclusions based on multiple layers of fuzzy evidence, so I'm putting zero relevance to the Tran hiring. They found a CMO, big deal. It's not like the guy is a Nobel laureate or something. He's some French guy who likes food.
All the hiring indicated to me was that Stoll plans to tough it out with another year of clinical trials, rather than the quick M+A route.